About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
O
Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Disease, Pregnancy (Nurses)
By
12th ESO-EONS Masterclass in Oncology Nursing
FEATURING
Olivia Pagani
August 14, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
17:04
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…
Feat.
G. Hortobagyi
Featured Video
18:15
Novartis Oncology
CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…
Feat.
G. Hortobagyi
Related Content
AUTOPLAY
ON
30:05
Cleveland Clinic Taussig Cancer Institute
Hormone Receptor Positive Advanced Breast Cancer Case 1: Management …
Feat.
J. Abraham,
R. Finn,
M. Dickler
14:37
Cleveland Clinic Taussig Cancer Institute
Hormone Receptor-Postive Advanced Breast Cancer Case 2: Patient with…
Feat.
J. Abraham
18:34
Cleveland Clinic Taussig Cancer Institute
Hormone Receptor-Positive Advanced Breast Cancer: Case 3: Treatment …
Feat.
J. Abraham,
R. Finn,
M. Dickler
11:40
Cleveland Clinic Taussig Cancer Institute
Hormone Receptor-Postive Advanced Breast Cancer Case 4: Patient with…
Feat.
J. Abraham,
R. Finn,
M. Dickler
16:44
Heather McArthur
Modern Immune Therapy Strategies for Triple-Negative Breast Cancer
17:54
Heather McArthur
Modern Immune Therapy in ER, HR+/HER2-, HER2+ Breast Cancer
24:03
Holy Cross 9th Annual Winter Oncology Symposium
Early Stage Breast Cancer - Comparison of Trials of Genomic Assays -…
Feat.
R. L. Mahtani
07:43
Dana-Farber Cancer Institute
Study of Abemaciclib for Patients with RB-Positive, Triple Negative …
Feat.
S. Goel
12:44
Holy Cross 9th Annual Winter Oncology Symposium
Emerging Targets in ER Positive Breast Cancer: CDK4/6 inhibitors, Bc…
Feat.
M. Abu-Khalaf
10:12
Holy Cross 9th Annual Winter Oncology Symposium
Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…
Feat.
M. Abu-Khalaf
32:33
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
Adjuvant Chemotherapy for HR+/HER2- Breast Cancer - How MINDACT, TAI…
Feat.
L. Carey
11:57
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
HR+/HER2- Breast Cancer - Who Needs Extended Adjuvant Endocrine Ther…
Feat.
L. Carey
11:07
Baltic and Eurasia Masterclass in Clinical Oncology
Advanced Breast Cancer: Endocrine Therapy as Preferred Option for HR…
Feat.
O. Pagani
10:00
12th ESO-EONS Masterclass in Oncology Nursing
Breast Cancer Global Epidemiology (Nurses)
Feat.
O. Pagani
13:36
Baltic and Eurasia Masterclass in Clinical Oncology
Systemic Treatment of TNBC: Staging, BRCAness, Chemotherapy Prognost…
Feat.
E. Kharchenko
13:38
2019 Scripps MD Anderson's Oncology Update
ASCO HR+/HER2 Breast Review: Practice Changing Monalessa-7 Trial Rib…
Feat.
J. Mortimer
18:53
Ingrid Mayer
Targeting FGFR in Endocrine and CDK4/6 Inhibitor Resistance in Breas…
15:19
ANCO’s ASCO Highlights 2019
ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Rib…
Feat.
H. Chew
16:29
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
NCCN Guidelines Update for ER+ Breast Cancer: CDK4/6 and PIK3CA Inhi…
Feat.
J. Abraham,
W. Gradishar
10:06
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherap…
Feat.
J. Abraham,
W. Gradishar
